stoxline Quote Chart Rank Option Currency Glossary
  
Predictive Oncology Inc. (POAI)
1.26  -0.09 (-6.67%)    06-13 16:00
Open: 1.34
High: 1.38
Volume: 77,397
  
Pre. Close: 1.35
Low: 1.21
Market Cap: 5(M)
Technical analysis
2024-06-13 4:45:40 PM
Short term     
Mid term     
Targets 6-month :  2.38 1-year :  3.02
Resists First :  2.03 Second :  2.58
Pivot price 1.49
Supports First :  1.14 Second :  0.95
MAs MA(5) :  1.27 MA(20) :  1.53
MA(100) :  2.25 MA(250) :  3.22
MACD MACD :  -0.2 Signal :  -0.1
%K %D K(14,3) :  11.5 D(3) :  10
RSI RSI(14): 38.8
52-week High :  7.11 Low :  1.12
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ POAI ] has closed above bottom band by 26.6%. Bollinger Bands are 24.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.38 - 1.39 1.39 - 1.39
Low: 1.2 - 1.2 1.2 - 1.21
Close: 1.25 - 1.26 1.26 - 1.27
Company Description

Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient's body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.

Headline News

Thu, 13 Jun 2024
Predictive Oncology (NASDAQ:POAI) Stock Price Crosses Below 200 Day Moving Average of $2.52 - Defense World

Tue, 04 Jun 2024
Predictive Oncology Launches Novel 3D Cell Technology to Accelerate Cancer Therapeutic Drug ... - WDRB

Tue, 28 May 2024
Predictive Oncology gains, to present positive results from a retrospective study - Seeking Alpha

Tue, 28 May 2024
Why Predictive Oncology (POAI) Stock Is Skyrocketing - Predictive Oncology (NASDAQ:POAI) - Benzinga

Thu, 23 May 2024
Predictive Oncology (NASDAQ:POAI) Stock Passes Below 200-Day Moving Average of $2.68 - Defense World

Wed, 15 May 2024
Predictive Oncology Inc. (POAI) Q1 2024 Earnings Call Transcript - Seeking Alpha

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Medical - Instruments & Supplies
Shares Out 0 (M)
Shares Float 4 (M)
Held by Insiders 3.64e+006 (%)
Held by Institutions 3.5 (%)
Shares Short 13 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.403e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -1 %
Return on Assets (ttm) 9.6 %
Return on Equity (ttm) -51.5 %
Qtrly Rev. Growth 1.96e+006 %
Gross Profit (p.s.) 56.31
Sales Per Share -98.32
EBITDA (p.s.) 0
Qtrly Earnings Growth -3.7 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -13 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.02
Price to Cash Flow 1.67
Stock Dividends
Dividend 0
Forward Dividend 120250
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android